Multivalent FV antibodies
The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS. 1 and 2 ).
1. A trispecific and tetravalent Fv antibody comprising a, first polypeptide consisting of six variable domains and a second polypeptide consisting of two variable domains,
wherein the first polypeptide comprises a first and a second variable domain forming a scFv-unit at the N-terminus,
said scFv-unit at the N-terminus is linked C-terminally to a third variable domain,
said third variable domain is linked C-terminally to a fourth variable domain,
said fourth variable domain is linked to a scFv-unit at the C-terminus, and
said scFv-unit is formed by a fifth and sixth variable domain, wherein the third and fourth variable domains of the first polypeptide associate with the two variable domains of the second polypeptide to form a diabody unit consisting of two pairs of variable domains,
wherein one pair is a pair of variable light chain domains (V L -V L ),
the other pair is a pair of variable heavy chains (V H -V H ) and
the diabody consists of two antigen binding sites and both antigen binding sites bind an antigen present on an immune effector cell.
2. The trispecific and tetravalent Fv antibody according to claim 1 , wherein the two variable domains in the pair of variable domains V L -V L and the pair of variable domains V H -V H are linked by a peptide linker consisting of 12 or less amino acid residues.
3. A trispecific and tetravalent Fv antibody comprising a diabody-unit consisting of two pairs of variable domains, wherein one pair is a pair of variable light chain domains (V L -V L ), the other pair is a pair of variable heavy chains (V H -V H ) and the diabody consists of two antigen binding sites and both antigen binding sites bind an antigen present on an immune effector cell, wherein one pair of variable domains is in a polypeptide comprising variable domains linked one after another, wherein said pair of two variable domains of the diabody-unit in the polypeptide comprising variable domains is associated with another pair of two variable domains of the polypeptide, wherein the polypeptide has eight variable domains linked one after another from the N-terminus to the C-terminus comprising,
a first and a second variable domain forming a scFv-unit at the N-terminus,
said scFv-unit at the N-terminus is linked C-terminally to a third variable domain,
said third variable domain is linked by a peptide linker consisting of 12 or less amino acid residues to a fourth variable domain,
said fourth variable domain is linked C-terminally to a fifth variable domain, said fifth variable domain is linked C-terminally to a sixth variable domain by a linker consisting of 12 or less amino acid residues, said sixth variable domain is linked C-terminally to a scFv-unit at the C-terminus and said scFv-unit is formed by a seventh and an eight variable domain.
4. A trispecific Fv antibody molecule comprising a diabody-unit consisting of two pairs of variable domains, wherein one pair is a pair of variable light chain domains (V L -V L ) and the other pair is a pair of variable heavy chains (V H -V H ) and the diabody consists of two antigen binding sites and both antigen binding sites bind an antigen present on an immune effector cell, wherein one pair of variable domains is in a polypeptide consisting of ten variable domains linked one after another and said one pair of juxtaposed variable domains is associated with the other pair of juxtaposed variable domains in a second polypeptide which consists of two variable domains, wherein the first polypeptide comprises a single chain diabody-unit at its N-terminus and a single chain diabody-unit at its C-terminus.
5. The trispecific and tetravalent Fv antibody molecule according to claim 1 ,
wherein
a Tag sequence is fused to the first polypeptide and a different Tag sequence is fused to the second polypeptide.
6. The multivalent Fv antibody molecule according to claim 3 , wherein said polypeptide has eight variable domains linked one after another from the N-terminus to the C-terminus, a first and a second variable domain forming a scFv-unit at the N-terminus, said scFv-unit at the N-terminus is linked C-terminally to a third variable domain, said third variable domain is linked by a peptide linker consisting of 12 or less amino acid residues to a fourth variable domain, said fourth variable domain is linked C-terminally to a fifth variable domain, said fifth variable domain is linked C-terminally to a sixth variable domain by a linker consisting of 12 or less amino acid residues, said sixth variable domain is linked C-terminally to a scFv-unit at the C-terminus and said scFv-unit is formed by a seventh and a eight variable domain.
7. The trispecific and tetravalent Fv antibody molecule according to claim 1 , wherein said variable domains in said diabody-unit have the same epitope specificity or different epitope specificities.
8. The trispecific and tetravalent Fv antibody molecule according to claim 1 , wherein the immune effector cell is selected from the group consisting of T cell, natural killer (NK) cell, gamma delta (gd) T cell, natural killer T (NKT) cell, granulocyte, monocyte, macrophage, dendritic cell, innate lymphoid cell (ILC) and antigen presenting cell.
9. The trispecific and tetravalent Fv antibody molecule according to claim 1 , wherein the Fv antibody comprises at least one specificity for a tumor antigen.
10. The trispecific and tetravalent Fv antibody molecule according to claim 9 , wherein the Fv antibody comprises specificities for two tumor antigens.
11. The trispecific and tetravalent Fv antibody molecule according to claim 1 , wherein the Fv antibody comprises at least one specificity for a viral antigen.
12. A medicament comprising the trispecific and tetravalent Fv antibody according to claim 1 .
13. The trispecific and tetravalent Fv antibody molecule according to claim 8 , wherein the antigen is selected from the group consisting of CD3, CD16 and CD16A.
14. The trispecific and tetravalent Fv antibody according to claim 1 , wherein the variable domains are arranged from the N-terminus to the C-terminus in an orientation selected from:
(a) V H -V L -V H -V H -V L -V H (first polypeptide) and V L -V L (second polypeptide);
(b) V L -V H -V H -V H -V H -V L (first polypeptide) and V L -V L (second polypeptide);
(c) V H -V L -V L -V L -V H -V L (first polypeptide) and V H -V H (second polypeptide);
(d) V L -V H -V L -V L -V H -V L (first polypeptide) and V H -V H (second polypeptide); or
(e) V H -V L -V L -V L -V L -V H (first polypeptide) and V H -V H (second polypeptide).
15. The trispecific and tetravalent Fv antibody molecule according to claim 9 , wherein the antibody molecule has an antigen-binding site specific for an antigen epitope on a soluble protein selected from the group consisting of growth factors, cytokines, chemokines, mitogens and albumins.
16. The trispecific and tetravalent Fv antibody molecule according to claim 5 , wherein the Tag sequences are selected from the group consisting of a His-Tag and SEQ ID NOs: 38-40.
17. The trispecific and tetravalent Fv antibody molecule according to claim 16 , wherein the Tag sequences are a His-Tag and SEQ ID NO: 38.
18. The trispecific and tetravalent Fv antibody molecule according to claim 5 , wherein the Fv antibody comprises at least one specificity for a tumor antigen.
19. The trispecific and tetravalent Fv antibody molecule according to claim 18 , wherein the Fv antibody comprises specificities for two tumor antigens.
20. The trispecific and tetravalent Fv antibody molecule according to claim 5 , wherein the immune effector cell is selected from the group consisting of T cell, natural killer (NK) cell, gamma delta (gd) T cell, natural killer T (NKT) cell, granulocyte, monocyte, macrophage, dendritic cell, innate lymphoid cell (ILC) and antigen presenting cell.
21. The trispecific and tetravalent Fv antibody molecule according to claim 20 , wherein the antigen is selected from the group consisting of CD3, CD16 and CD16A.
22. The trispecific and tetravalent Fv antibody according to claim 5 , wherein the variable domains are arranged from the N-terminus to the C-terminus in an orientation selected from:
(a) V H -V L -V H -V H -V L -V H (first polypeptide) and V L -V L (second polypeptide);
(b) V L -V H -V H -V H -V H -V L (first polypeptide) and V L -V L (second polypeptide);
(c) V H -V L -V L -V L -V H -V L (first polypeptide) and V H -V H (second polypeptide);
(d) V L -V H -V L -V L -V H -V L (first polypeptide) and V H -V H (second polypeptide); or
(e) V H -V L -V L -V L -V L -V H (first polypeptide) and V H -V H (second polypeptide).
23. The trispecific Fv antibody molecule according to claim 4 , wherein the diabody consists of two antigen binding sites and both antigen binding sites bind an antigen present on an immune effector cell.
24. The trispecific Fv antibody molecule according to claim 23 , wherein the immune effector cell is selected from the group consisting of T cell, natural killer (NK) cell, gamma delta (gd) T cell, natural killer T (NKT) cell, granulocyte, monocyte, macrophage, dendritic cell, innate lymphoid cell (ILC) and antigen presenting cell.
25. The trispecific Fv antibody molecule according to claim 24 , wherein the antigen is selected from the group consisting of CD3, CD16 and CD16A.